Global Biosimulation Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 – 2022
Biosimulation is explained as a computer-aided mathematical simulation of biological processes and systems and hence is an integral part of systems biology. The main aim of Biosimulation is model-based prediction of the behavior and the dynamics of biological systems e.g. the response of an organ or a single cell towards a chemical. It is a predictive tool and used in discovery stage to determine the future outcomes of current experimental trials.
The demand for Biosimulation market is expected to increase in forecasted period due to increase in the factors such as use of personalized medicine.
Factors that are driving the market are: Increase in the use of personalized medicine also continuous research and development is going on in the field which has led to the improvement and simulation of modeling tools, also the growth in the biotechnological and pharmaceutical industries has helped Biosimulation industry to grow. Also, the industry is expecting growth due to the boom in drugs market as a result of increase in ageing population and increasing number of chronic diseases. Some of the factors which are restraining the market are shortage of skilled professionals, higher cost of the process, lack of standardized tools and applications and limited knowledge about biological process.
The market of Biosimulation market is segmented on the basis of products, end user, application, drug development. Geographically the market is divided in to North America (US, Canada), Europe (UK, Italy, Spain, France, Germany, rest of Europe), Asia-Pacific (India, Japan, Australia, China, Korea, Rest of Asia Pacific) and Rest of World (Latin America, MENA and Africa). The key providers of biosimulation technology are Certara, Biovia, Dassault Systèmes.
Companies profile include
1. Certara USA, Inc.
2. Rhenovia Pharma Ltd.
3. Physiomics PLC
4. Genedata Ag
5. Entelos Holding Corporation
6. Chemical Computing Group, Inc.
7. Advanced Chemistry Development, Inc.
8. Schrödinger Inc.
9. Dassault Systèmes SA
10. Simulation Plus Inc.
11. Biovia (Formerly Accelrys)
12. In silico biosciences
13. Inhibox
14. Leadinvent Technologies
15. Leadscope
16. Nimbus therapeutics
17. Open eye Scientific software
18. Physiomics Plc.
19. Rhenovia Pharma
20. Genedata
This Occams Research Report covers
1. Historical data
2.Revenue forecasts, growth rates and CAGR up to 2022
3.Industry Analysis
4.Competitive Analysis
5. Key geographic growth data
The demand for Biosimulation market is expected to increase in forecasted period due to increase in the factors such as use of personalized medicine.
Factors that are driving the market are: Increase in the use of personalized medicine also continuous research and development is going on in the field which has led to the improvement and simulation of modeling tools, also the growth in the biotechnological and pharmaceutical industries has helped Biosimulation industry to grow. Also, the industry is expecting growth due to the boom in drugs market as a result of increase in ageing population and increasing number of chronic diseases. Some of the factors which are restraining the market are shortage of skilled professionals, higher cost of the process, lack of standardized tools and applications and limited knowledge about biological process.
The market of Biosimulation market is segmented on the basis of products, end user, application, drug development. Geographically the market is divided in to North America (US, Canada), Europe (UK, Italy, Spain, France, Germany, rest of Europe), Asia-Pacific (India, Japan, Australia, China, Korea, Rest of Asia Pacific) and Rest of World (Latin America, MENA and Africa). The key providers of biosimulation technology are Certara, Biovia, Dassault Systèmes.
Companies profile include
1. Certara USA, Inc.
2. Rhenovia Pharma Ltd.
3. Physiomics PLC
4. Genedata Ag
5. Entelos Holding Corporation
6. Chemical Computing Group, Inc.
7. Advanced Chemistry Development, Inc.
8. Schrödinger Inc.
9. Dassault Systèmes SA
10. Simulation Plus Inc.
11. Biovia (Formerly Accelrys)
12. In silico biosciences
13. Inhibox
14. Leadinvent Technologies
15. Leadscope
16. Nimbus therapeutics
17. Open eye Scientific software
18. Physiomics Plc.
19. Rhenovia Pharma
20. Genedata
This Occams Research Report covers
1. Historical data
2.Revenue forecasts, growth rates and CAGR up to 2022
3.Industry Analysis
4.Competitive Analysis
5. Key geographic growth data
1. INTRODUCTION
1.1 Executive Summary
1.2 Estimation methodology
2. MARKET OVERVIEW
2.1 Market definition and scope
2.2 Key findings
2.3 Parametric analysis
2.3.1 Personalized medicine market
2.3.2 Investment in R&D by various organizations
2.3.3 Healthcare expenditure across geographies
2.3.4 Disposable income of top emerging economies
2.4 Key market insights
2.4.1 Top 3 emerging countries
2.4.2 Top 3 revenue generating segments
2.4.3 Market trends
2.4.4 Winning strategy
2.4.5 Pipeline analysis
2.5 R & D Scenario
2.6 Competitive intelligence
2.6.1 Market share analysis
2.6.2 Top winning strategies
2.6.3 Case study; top competitive moves
2.7 Value chain analysis
2.8 Key buying criteria
2.9 Strategic recommendation
2.10 Strategic conclusion
3. MARKET DETERMINANTS
3.1 Market driver
3.1.1 Increased use of personalized medicine
3.1.2 Research and development in the field
3.1.3 Growth in pharmaceutical and biotechnological industries.
3.1.4 Advent of improved simulation and modeling tools
3.1.5 Growing incidence of chronic diseases.
3.2 Market Restraints
3.2.1 Shortage of skilled professionals
3.2.2 High R&D costs of biosimulation software development
3.2.3 Lack of standardized tools and applications
3.3 Market opportunities
3.3.1 Drive in drugs market due to ageing population
3.3.2 Partnership among pharmaceutical players
3.4 Market challenges
3.4.1 Limited knowledge of biological process
3.4.2 Higher cost
4. SECTOR ANALYSIS
4.1 Parent market analysis
4.2 Competitor market analysis
4.3 Alternative market analysis
5. MARKET SEGMENTATION
5.1 Global Biosimulation market on the basis of products, 2014-2021,($ millions)
5.1.1 Global Biosimulation market on the basis of services, 2014-2021,($ millions)
5.1.2 Global Biosimulation market on the basis of Trial Design software, 2014-2021,($ millions)
5.1.3 Global Biosimulation market on the basis of PBPK modeling, 2014-2021,($ millions)
5.1.4 Global Biosimulation market on the basis of Toxicity prediction software, 2014-2021,($ millions)
5.1.5 Global Biosimulation market on the basis of Molecular modeling and simulation software, 2014-2021,($ millions)
5.2 Global Biosimulation market on the basis of end user, 2014-2021($ millions)
5.2.1 Global Biosimulation market on the basis of Research institutes, 2014-2021,($ millions)
5.2.2 Global Biosimulation market on the basis of Pharmaceutical biotechnological companies, 2014-2021, ($ millions)
5.2.3 Global Biosimulation market on the basis of Regulatory athourities, 2014-2021,($ millions)
5.3 Global Biosimulation market on the basis of application, 2014-2021 ($ millions)
5.3.1 Global Biosimulation market on the basis of Drug development, 2014-2021,($ millions)
5.3.2 Global Biosimulation market on the basis of PK/PD, 2014-2021,($ millions)
5.3.3 Global Biosimulation market on the basis of Clinical trials, 2014-2021,($ millions)
5.3.4 Global Biosimulation market on the basis of Lead identification and Optimization, 2014-2021,($ millions)
5.4 Global biosimulation market on the basis of Drug development,2014-2021 ($ millions)
5.4.1 Global Biosimulation market on the basis of Preclinical testing, 2014-2021,($ millions)
5.4.2 Global Biosimulation market on the basis of Inpatient validation, 2014-2021,($ millions)
6 GEOGRAPHIC ANALYSIS
6.1 North America market, 2014-2021,($ millions)
6.1.1 U.S Biosimulation market,2014-2021,($millions)
6.1.2 Canada Biosimulation market,2014 -2021,($millions)
6.2 Europe Biosimulation market,2014 -2021,($millions)
6.2.1 U.K Biosimulation market,2014 -2021,($millions)
6.2.2 Germany Biosimulation market,2014 -2021,($millions)
6.2.3 France Biosimulation market,2014 -2021,($millions)
6.2.4 Spain market Biosimulation,2014 -2021,($millions)
6.2.5 Italy market Biosimulation,2014 -2021,($millions)
6.3 Asia Pacific
6.3.1 China Biosimulation market,2014 -2021,($millions)
6.3.2 India Biosimulation market,2014 -2021,($millions)
6.3.3 Korea Biosimulation market,2014 -2021,($millions)
6.3.4 Japan Biosimulation market,2014 -2021,($millions)
6.3.5 Australia Biosimulation market,2014 -2021,($millions)
6.3.6 Rest of APAC
6.4 Rest of the world
7. COMPANY PROFILING
7.1 Certara USA, Inc.
7.2 Rhenovia Pharma Ltd.
7.3 Physiomics PLC
7.4 Genedata Ag
7.5 Entelos Holding Corporation
7.6 Chemical Computing Group, Inc.
7.7 Advanced Chemistry Development, Inc.
7.8 Schrödinger Inc.
7.9 Dassault Systèmes SA
7.10 Simulation Plus Inc.
7.11 Biovia (Formerly Accelrys)
7.12 In silico biosciences
7.13 Inhibox
7.14 Leadinvent Technologies
7.15 Leadscope
7.16 Nimbus therapeutics
7.17 Open eye Scientific software
7.18 Physiomics Plc.
7.19 Rhenovia Pharma
7.20 Genedata
1.1 Executive Summary
1.2 Estimation methodology
2. MARKET OVERVIEW
2.1 Market definition and scope
2.2 Key findings
2.3 Parametric analysis
2.3.1 Personalized medicine market
2.3.2 Investment in R&D by various organizations
2.3.3 Healthcare expenditure across geographies
2.3.4 Disposable income of top emerging economies
2.4 Key market insights
2.4.1 Top 3 emerging countries
2.4.2 Top 3 revenue generating segments
2.4.3 Market trends
2.4.4 Winning strategy
2.4.5 Pipeline analysis
2.5 R & D Scenario
2.6 Competitive intelligence
2.6.1 Market share analysis
2.6.2 Top winning strategies
2.6.3 Case study; top competitive moves
2.7 Value chain analysis
2.8 Key buying criteria
2.9 Strategic recommendation
2.10 Strategic conclusion
3. MARKET DETERMINANTS
3.1 Market driver
3.1.1 Increased use of personalized medicine
3.1.2 Research and development in the field
3.1.3 Growth in pharmaceutical and biotechnological industries.
3.1.4 Advent of improved simulation and modeling tools
3.1.5 Growing incidence of chronic diseases.
3.2 Market Restraints
3.2.1 Shortage of skilled professionals
3.2.2 High R&D costs of biosimulation software development
3.2.3 Lack of standardized tools and applications
3.3 Market opportunities
3.3.1 Drive in drugs market due to ageing population
3.3.2 Partnership among pharmaceutical players
3.4 Market challenges
3.4.1 Limited knowledge of biological process
3.4.2 Higher cost
4. SECTOR ANALYSIS
4.1 Parent market analysis
4.2 Competitor market analysis
4.3 Alternative market analysis
5. MARKET SEGMENTATION
5.1 Global Biosimulation market on the basis of products, 2014-2021,($ millions)
5.1.1 Global Biosimulation market on the basis of services, 2014-2021,($ millions)
5.1.2 Global Biosimulation market on the basis of Trial Design software, 2014-2021,($ millions)
5.1.3 Global Biosimulation market on the basis of PBPK modeling, 2014-2021,($ millions)
5.1.4 Global Biosimulation market on the basis of Toxicity prediction software, 2014-2021,($ millions)
5.1.5 Global Biosimulation market on the basis of Molecular modeling and simulation software, 2014-2021,($ millions)
5.2 Global Biosimulation market on the basis of end user, 2014-2021($ millions)
5.2.1 Global Biosimulation market on the basis of Research institutes, 2014-2021,($ millions)
5.2.2 Global Biosimulation market on the basis of Pharmaceutical biotechnological companies, 2014-2021, ($ millions)
5.2.3 Global Biosimulation market on the basis of Regulatory athourities, 2014-2021,($ millions)
5.3 Global Biosimulation market on the basis of application, 2014-2021 ($ millions)
5.3.1 Global Biosimulation market on the basis of Drug development, 2014-2021,($ millions)
5.3.2 Global Biosimulation market on the basis of PK/PD, 2014-2021,($ millions)
5.3.3 Global Biosimulation market on the basis of Clinical trials, 2014-2021,($ millions)
5.3.4 Global Biosimulation market on the basis of Lead identification and Optimization, 2014-2021,($ millions)
5.4 Global biosimulation market on the basis of Drug development,2014-2021 ($ millions)
5.4.1 Global Biosimulation market on the basis of Preclinical testing, 2014-2021,($ millions)
5.4.2 Global Biosimulation market on the basis of Inpatient validation, 2014-2021,($ millions)
6 GEOGRAPHIC ANALYSIS
6.1 North America market, 2014-2021,($ millions)
6.1.1 U.S Biosimulation market,2014-2021,($millions)
6.1.2 Canada Biosimulation market,2014 -2021,($millions)
6.2 Europe Biosimulation market,2014 -2021,($millions)
6.2.1 U.K Biosimulation market,2014 -2021,($millions)
6.2.2 Germany Biosimulation market,2014 -2021,($millions)
6.2.3 France Biosimulation market,2014 -2021,($millions)
6.2.4 Spain market Biosimulation,2014 -2021,($millions)
6.2.5 Italy market Biosimulation,2014 -2021,($millions)
6.3 Asia Pacific
6.3.1 China Biosimulation market,2014 -2021,($millions)
6.3.2 India Biosimulation market,2014 -2021,($millions)
6.3.3 Korea Biosimulation market,2014 -2021,($millions)
6.3.4 Japan Biosimulation market,2014 -2021,($millions)
6.3.5 Australia Biosimulation market,2014 -2021,($millions)
6.3.6 Rest of APAC
6.4 Rest of the world
7. COMPANY PROFILING
7.1 Certara USA, Inc.
7.2 Rhenovia Pharma Ltd.
7.3 Physiomics PLC
7.4 Genedata Ag
7.5 Entelos Holding Corporation
7.6 Chemical Computing Group, Inc.
7.7 Advanced Chemistry Development, Inc.
7.8 Schrödinger Inc.
7.9 Dassault Systèmes SA
7.10 Simulation Plus Inc.
7.11 Biovia (Formerly Accelrys)
7.12 In silico biosciences
7.13 Inhibox
7.14 Leadinvent Technologies
7.15 Leadscope
7.16 Nimbus therapeutics
7.17 Open eye Scientific software
7.18 Physiomics Plc.
7.19 Rhenovia Pharma
7.20 Genedata
LIST OF TABLES
1. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PRODUCTS 2014-2022 ($ MILLION)
2. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PRODUCTS BY GEOGRAPHY 2014-2022 ($ MILLION)
3. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF SERVICES BY GEOGRAPHY 2014-2022 ($ MILLION)
4. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF TRIAL DESIGN SOFTWARE BY GEOGRAPHY 2014-2022 ($ MILLION)
5. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PBPK MODELING BY GEOGRAPHY 2014-2022 ($ MILLION)
6. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF TOXICITY PREDICTION SOFTWARE BY GEOGRAPHY 2014-2022 ($ MILLION)
7. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF MOLECULAR MODELING AND SIMULATION SOFTWARE BY GEOGRAPHY 2014-2022 ($ MILLION)
8. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF END USER BY GEOGRAPHY 2014-2022 ($ MILLION)
9. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF END USER 2014-2022 ($ MILLION)
10. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF USAGE IN RESEARCH INSTITUTES BY GEOGYAPHY 2014-2022 ($ MILLION)
11. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF USAGE IN PHARMACEUTICAL BIOTECHNOLOGICAL COMPANIES BY GEOGRAPHY, 2014-2021, ($ MILLIONS)
12. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF USAGE IN REGULATORY AUTHORITIES BY GEOGRAPHY 2014-2022 ($ MILLION)
13. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF APPLICATION, 2014-2021 ($ MILLIONS)
14. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF APPLICATION BY GEOGRAPHY, 2014-2021 ($ MILLIONS
15. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF DRUG DEVELOPMENT BY GEOGRAPHY 2014-2022 ($ MILLION)
16. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PK/PD BY GEOGRAPHY 2014-2022 ($ MILLION)
17. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF CLINICAL TRIALS BY GEOGRAPHY 2014-2022 ($ MILLION)
18. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF LEAD IDENTIFICATION AND OPTIMIZATION BY GEOGRAPHY 2014-2022 ($ MILLION)
19. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF DRUG DEVELOPMENT BY GEOGRAPHY 2014-2022 ($ MILLION)
20. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF DRUG DEVELOPMENT 2014-2022 ($ MILLION)
21. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PRECLINICAL TESTING BY GEOGRAPHY 2014-2022 ($ MILLION)
22. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF INPATIENT VALIDATION BY GEOGRAPHY 2014-2022 ($ MILLION)
1. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PRODUCTS 2014-2022 ($ MILLION)
2. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PRODUCTS BY GEOGRAPHY 2014-2022 ($ MILLION)
3. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF SERVICES BY GEOGRAPHY 2014-2022 ($ MILLION)
4. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF TRIAL DESIGN SOFTWARE BY GEOGRAPHY 2014-2022 ($ MILLION)
5. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PBPK MODELING BY GEOGRAPHY 2014-2022 ($ MILLION)
6. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF TOXICITY PREDICTION SOFTWARE BY GEOGRAPHY 2014-2022 ($ MILLION)
7. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF MOLECULAR MODELING AND SIMULATION SOFTWARE BY GEOGRAPHY 2014-2022 ($ MILLION)
8. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF END USER BY GEOGRAPHY 2014-2022 ($ MILLION)
9. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF END USER 2014-2022 ($ MILLION)
10. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF USAGE IN RESEARCH INSTITUTES BY GEOGYAPHY 2014-2022 ($ MILLION)
11. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF USAGE IN PHARMACEUTICAL BIOTECHNOLOGICAL COMPANIES BY GEOGRAPHY, 2014-2021, ($ MILLIONS)
12. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF USAGE IN REGULATORY AUTHORITIES BY GEOGRAPHY 2014-2022 ($ MILLION)
13. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF APPLICATION, 2014-2021 ($ MILLIONS)
14. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF APPLICATION BY GEOGRAPHY, 2014-2021 ($ MILLIONS
15. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF DRUG DEVELOPMENT BY GEOGRAPHY 2014-2022 ($ MILLION)
16. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PK/PD BY GEOGRAPHY 2014-2022 ($ MILLION)
17. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF CLINICAL TRIALS BY GEOGRAPHY 2014-2022 ($ MILLION)
18. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF LEAD IDENTIFICATION AND OPTIMIZATION BY GEOGRAPHY 2014-2022 ($ MILLION)
19. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF DRUG DEVELOPMENT BY GEOGRAPHY 2014-2022 ($ MILLION)
20. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF DRUG DEVELOPMENT 2014-2022 ($ MILLION)
21. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PRECLINICAL TESTING BY GEOGRAPHY 2014-2022 ($ MILLION)
22. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF INPATIENT VALIDATION BY GEOGRAPHY 2014-2022 ($ MILLION)
LIST OF FIGURES
1. U.S BIOSIMULATION MARKET 2014-2022 ($ MILLION)
2. CANADA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
3. U.K BIOSIMULATION MARKET 2014-2022 ($ MILLION)
4. GERMANY BIOSIMULATION MARKET 2014-2022 ($ MILLION)
5. FRANCE BIOSIMULATION MARKET 2014-2022 ($ MILLION)
6. SPAIN MARKET BIOSIMULATION 2014-2022 ($ MILLION)
7. ITALY MARKET BIOSIMULATION 2014-2022 ($ MILLION)
8. CHINA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
9. INDIA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
10. KOREA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
11. JAPAN BIOSIMULATION MARKET 2014-2022 ($ MILLION)
12. AUSTRALIA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
13. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF SERVICES 2014-2022 ($ MILLION)
14. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF TRIAL DESIGN SOFTWARE 2014-2022 ($ MILLION)
15. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PBPK MODELING 2014-2022 ($ MILLION)
16. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF TOXICITY PREDICTION SOFTWARE 2014-2022 ($ MILLION)
17. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF MOLECULAR MODELING AND SIMULATION SOFTWARE 2014-2022 ($ MILLION)
18. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF RESEARCH INSTITUTES 2014-2022 ($ MILLION)
19. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PHARMACEUTICAL BIOTECHNOLOGICAL COMPANIES, 2014-2021, ($ MILLIONS)
20. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF REGULATORY ATHOURITIES 2014-2022 ($ MILLION)
21. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF DRUG DEVELOPMENT 2014-2022 ($ MILLION)
22. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PK/PD 2014-2022 ($ MILLION)
23. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF CLINICAL TRIALS 2014-2022 ($ MILLION)
24. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF LEAD IDENTIFICATION AND OPTIMIZATION 2014-2022 ($ MILLION)
25. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PRECLINICAL TESTING 2014-2022 ($ MILLION)
26. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF INPATIENT VALIDATION 2014-2022 ($ MILLION)
COMPANIES MENTIONED
1 Certara USA, Inc
2 Rhenovia Pharma Ltd
3 Physiomics PLC
4 Genedata Ag
5 Entelos Holding Corporation
6 Chemical Computing Group, Inc
7 Advanced Chemistry Development, Inc
8 Schrödinger Inc
9 Dassault Systèmes SA
10 Simulation Plus Inc
11 Biovia (Formerly Accelrys)
12 In silico biosciences
13 Inhibox
14 Leadinvent Technologies
15 Leadscope
16 Nimbus therapeutics
17 Open eye Scientific software
18 Physiomics Plc
19 Rhenovia Pharma
20 Genedata
1. U.S BIOSIMULATION MARKET 2014-2022 ($ MILLION)
2. CANADA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
3. U.K BIOSIMULATION MARKET 2014-2022 ($ MILLION)
4. GERMANY BIOSIMULATION MARKET 2014-2022 ($ MILLION)
5. FRANCE BIOSIMULATION MARKET 2014-2022 ($ MILLION)
6. SPAIN MARKET BIOSIMULATION 2014-2022 ($ MILLION)
7. ITALY MARKET BIOSIMULATION 2014-2022 ($ MILLION)
8. CHINA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
9. INDIA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
10. KOREA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
11. JAPAN BIOSIMULATION MARKET 2014-2022 ($ MILLION)
12. AUSTRALIA BIOSIMULATION MARKET 2014-2022 ($ MILLION)
13. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF SERVICES 2014-2022 ($ MILLION)
14. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF TRIAL DESIGN SOFTWARE 2014-2022 ($ MILLION)
15. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PBPK MODELING 2014-2022 ($ MILLION)
16. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF TOXICITY PREDICTION SOFTWARE 2014-2022 ($ MILLION)
17. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF MOLECULAR MODELING AND SIMULATION SOFTWARE 2014-2022 ($ MILLION)
18. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF RESEARCH INSTITUTES 2014-2022 ($ MILLION)
19. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PHARMACEUTICAL BIOTECHNOLOGICAL COMPANIES, 2014-2021, ($ MILLIONS)
20. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF REGULATORY ATHOURITIES 2014-2022 ($ MILLION)
21. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF DRUG DEVELOPMENT 2014-2022 ($ MILLION)
22. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PK/PD 2014-2022 ($ MILLION)
23. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF CLINICAL TRIALS 2014-2022 ($ MILLION)
24. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF LEAD IDENTIFICATION AND OPTIMIZATION 2014-2022 ($ MILLION)
25. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF PRECLINICAL TESTING 2014-2022 ($ MILLION)
26. GLOBAL BIOSIMULATION MARKET ON THE BASIS OF INPATIENT VALIDATION 2014-2022 ($ MILLION)
COMPANIES MENTIONED
1 Certara USA, Inc
2 Rhenovia Pharma Ltd
3 Physiomics PLC
4 Genedata Ag
5 Entelos Holding Corporation
6 Chemical Computing Group, Inc
7 Advanced Chemistry Development, Inc
8 Schrödinger Inc
9 Dassault Systèmes SA
10 Simulation Plus Inc
11 Biovia (Formerly Accelrys)
12 In silico biosciences
13 Inhibox
14 Leadinvent Technologies
15 Leadscope
16 Nimbus therapeutics
17 Open eye Scientific software
18 Physiomics Plc
19 Rhenovia Pharma
20 Genedata
